Peptide Library

Human study PLS-00248

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

Other design · Not reported participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDregistry entry · NCT07487363 (RECRUITING, no results posted, planned enrollment 80)

Design and participants

Design
Other design
Population
Adults with stable atherosclerotic cardiovascular disease and endothelial dysfunction, per the registered conditions; eligibility details are not in the record.
Conditions
Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
Planned enrollment (registry)
80
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • TB-500 (intervention) · tb-500 · TB-500, described in the registered title as the thymosin beta-4 17-23 fragment · Not reported assigned
  • Placebo (comparator) · Placebo · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Cardiovascular biomarkers

unclear outcome · surrogate · Not specified in the record; the title refers only to cardiovascular biomarkers

  • No results reported.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • other: The record does not state the allocation method or blinding, although a placebo arm is registered. Randomization therefore cannot be confirmed.
  • inappropriate endpoint: The title indicates cardiovascular biomarker endpoints, which are surrogate outcomes rather than patient-important ones.
  • small or imprecise: Planned enrollment is an estimated 80 participants in a phase 1/2 trial, so any future estimates may be imprecise.
  • inappropriate population: Population is stable ASCVD with endothelial dysfunction, not soft-tissue injury.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: NCT NCT07487363, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT07487363, registry (study_type, phases and interventions fields) · extracted by AI (automated, not verified by a person)
  • limitations: NCT NCT07487363, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
  • outcomes: NCT NCT07487363, title (registered study title) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT07487363, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT07487363, registry (conditions field) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).